Effects of tirapazamine on experimental colorectal liver metastases after radiofrequency ablation.

The British journal of surgery 20120401

Effects of tirapazamine on experimental colorectal liver metastases after radiofrequency ablation (Br J Surg 2012; 99: 567-575).

The British journal of surgery 20120401

On the reaction mechanism of tirapazamine reduction chemistry: unimolecular N-OH homolysis, stepwise dehydration, or triazene ring-opening.

Chemical research in toxicology 20120319

Electron and spin-density analysis of tirapazamine reduction chemistry.

Chemical research in toxicology 20120319

The 2-nitroimidazole EF5 is a biomarker for oxidoreductases that activate the bioreductive prodrug CEN-209 under hypoxia.

Clinical cancer research : an official journal of the American Association for Cancer Research 20120315

Prognostic and predictive significance of plasma HGF and IL-8 in a phase III trial of chemoradiation with or without tirapazamine in locoregionally advanced head and neck cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research 20120315

Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302.

Molecular cancer therapeutics 20120301

Homologous recombination repair-dependent cytotoxicity of the benzotriazine di-N-oxide CEN-209: comparison with other hypoxia-activated prodrugs.

Biochemical pharmacology 20120301

DNA strand cleavage by the phenazine di-N-oxide natural product myxin under both aerobic and anaerobic conditions.

Chemical research in toxicology 20120113

Prognostic significance of plasma osteopontin in patients with locoregionally advanced head and neck squamous cell carcinoma treated on TROG 02.02 phase III trial.

Clinical cancer research : an official journal of the American Association for Cancer Research 20120101

Yeast toxicogenomics: genome-wide responses to chemical stresses with impact in environmental health, pharmacology, and biotechnology.

Frontiers in genetics 20120101

Targeting tumor perfusion and oxygenation to improve the outcome of anticancer therapy.

Frontiers in pharmacology 20120101

Tirapazamine-doxorubicin interaction referring to heart oxidative stress and Ca²⁺ balance protein levels.

Oxidative medicine and cellular longevity 20120101

Usefulness of combined treatment with continuous administration of tirapazamine and mild temperature hyperthermia in γ-ray irradiation in terms of local tumour response and lung metastatic potential.

International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 20120101

Enhanced antitumor effect of tirapazamine delivered intraperitoneally to VX2 liver tumor-bearing rabbits subjected to transarterial hepatic embolization.

Cardiovascular and interventional radiology 20111201

Selenium is a modulator of circadian clock that protects mice from the toxicity of a chemotherapeutic drug via upregulation of the core clock protein, BMAL1.

Oncotarget 20111201

Generation of oxygen gradients in microfluidic devices for cell culture using spatially confined chemical reactions.

Lab on a chip 20111107

Quinoxalino[2,3-c]cinnolines and their 5-N-oxide: alkoxylation of methyl-substituted quinoxalino[2,3-c]cinnolines to acetals and orthoesters.

The Journal of organic chemistry 20111021

Radiotherapy and temozolomide for newly diagnosed glioblastoma and anaplastic astrocytoma: validation of Radiation Therapy Oncology Group-Recursive Partitioning Analysis in the IMRT and temozolomide era.

Journal of neuro-oncology 20110801

Hypoxia-targeting by tirapazamine (TPZ) induces preferential growth inhibition of nasopharyngeal carcinoma cells with Chk1/2 activation.

Investigational new drugs 20110601

Targeting castration-induced tumour hypoxia enhances the acute effects of castration therapy in a rat prostate cancer model.

BJU international 20110601

Hypoxia-dependent retinal toxicity of NLCQ-1 (NSC 709257) in BALB/c mice. Comparison with tirapazamine.

Basic & clinical pharmacology & toxicology 20110601

Uroporphyrinogen decarboxylase: optimizing radiotherapy for head and neck cancer.

Future oncology (London, England) 20110501

Early toxicity predicts long-term survival in high-grade glioma.

British journal of cancer 20110426

Synthesis, hypoxia-selective cytotoxicity of new 3-amino-1,2,4-benzotriazine-1,4-dioxide derivatives.

European journal of medicinal chemistry 20110301

High-throughput 3D spheroid culture and drug testing using a 384 hanging drop array.

The Analyst 20110207

Evaluation of the efficacy of radiation-modifying compounds using γH2AX as a molecular marker of DNA double-strand breaks.

Genome integrity 20110101

Investigation of tumor hypoxia using a two-enzyme system for in vitro generation of oxygen deficiency.

Radiation oncology (London, England) 20110101

Transport processes of radiopharmaceuticals and -modulators.

Radiation oncology (London, England) 20110101

Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104.

PloS one 20110101

A mathematical model for targeting chemicals to tissues by exploiting complex degradation.

Biology direct 20110101

Regulation of DNA repair mechanism in human glioma xenograft cells both in vitro and in vivo in nude mice.

PloS one 20110101

Novel Phenazine 5,10-Dioxides Release OH in Simulated Hypoxia and Induce Reduction of Tumour Volume In Vivo.

ISRN pharmacology 20110101

Targeting hypoxic tumour cells to overcome metastasis.

BMC cancer 20110101

Metronomic Cyclophosphamide and Methotrexate Chemotherapy Combined with 1E10 Anti-Idiotype Vaccine in Metastatic Breast Cancer.

International journal of breast cancer 20110101

Combined modality approaches in the management of adult glioblastoma.

Frontiers in oncology 20110101

Strategies for discovery of small molecule radiation protectors and radiation mitigators.

Frontiers in oncology 20110101

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20101201

Henry S. Kaplan Distinguished Scientist Award Lecture 2007. The remarkable yin and yang of tumour hypoxia.

International journal of radiation biology 20101101

Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research 20101015

Strategies to promote translational research within the European Organisation for Research and Treatment of Cancer (EORTC) Head and Neck Cancer Group: a report from the Translational Research Subcommittee.

Annals of oncology : official journal of the European Society for Medical Oncology 20101001

Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100920

p16 Expression as a predictive biomarker of hypoxic cell-sensitizing agents in oropharyngeal cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100920

Substantial improvement in UK cervical cancer survival with chemoradiotherapy: results of a Royal College of Radiologists' audit.

Clinical oncology (Royal College of Radiologists (Great Britain)) 20100901

Medicinal electronomics bricolage design of hypoxia-targeting antineoplastic drugs and invention of boron tracedrugs as innovative future-architectural drugs.

Anticancer research 20100901

Correlation of pharmacokinetic features and tissue distribution with toxicity of Q39, a hypoxic cell cytotoxic agent.

Die Pharmazie 20100901

The hypoxia-selective cytotoxin NLCQ-1 (NSC 709257) controls metastatic disease when used as an adjuvant to radiotherapy.

British journal of cancer 20100713

Phase 1 study of tirapazamine in combination with radiation and weekly cisplatin in patients with locally advanced cervical cancer.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20100701

The tumor microenvironment in non-small-cell lung cancer.

Seminars in radiation oncology 20100701

Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100620

Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100620

Review of positron emission tomography tracers for imaging of tumor hypoxia.

Cancer biotherapy & radiopharmaceuticals 20100601

DNA strand cleaving properties and hypoxia-selective cytotoxicity of 7-chloro-2-thienylcarbonyl-3-trifluoromethylquinoxaline 1,4-dioxide.

Bioorganic & medicinal chemistry 20100501

Characterization of radicals formed following enzymatic reduction of 3-substituted analogues of the hypoxia-selective cytotoxin 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine).

Journal of the American Chemical Society 20100303

Expression of hypoxia-inducible factor 1 alpha in thyroid carcinomas.

Endocrine-related cancer 20100301

Regulation of hypoxia-induced mRNA expressions of HIF-1alpha and osteopontin and in vitro radiosensitization by tirapazamine in human nasopharyngeal carcinoma HNE-1 and CNE-1 cells.

Chinese journal of cancer 20100201

Residual gammaH2AX foci as an indication of lethal DNA lesions.

BMC cancer 20100101

Effectiveness of combined modality radiotherapy of orthotopic human squamous cell carcinomas in Nu/Nu mice using cetuximab, tirapazamine and MnSOD-plasmid liposome gene therapy.

In vivo (Athens, Greece) 20100101

Hypoxia-inducible factor-1 as a therapeutic target in endometrial cancer management.

Obstetrics and gynecology international 20100101

Design of novel hypoxia-targeting IDO hybrid inhibitors conjugated with an unsubstituted L-TRP as an IDO affinity moiety.

Advances in experimental medicine and biology 20100101

Architectural heterogeneity in tumors caused by differentiation alters intratumoral drug distribution and affects therapeutic synergy of antiangiogenic organoselenium compound.

Journal of oncology 20100101

XQ2, a novel TPZ derivative, induced G2/M phase arrest and apoptosis under hypoxia in non-small cell lung cancer cells.

Bioscience, biotechnology, and biochemistry 20100101

Hypoxia-specific targets in cancer therapy: role of splice variants.

BMC medicine 20100101

The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer.

Biologics : targets & therapy 20100101

A phase II randomized trial comparing radiotherapy with concurrent weekly cisplatin or weekly paclitaxel in patients with advanced cervical cancer.

Radiation oncology (London, England) 20100101

Suppression of hypoxia-inducible factor 1α (HIF-1α) by tirapazamine is dependent on eIF2α phosphorylation rather than the mTORC1/4E-BP1 pathway.

PloS one 20100101

VEGFR2 heterogeneity and response to anti-angiogenic low dose metronomic cyclophosphamide treatment.

BMC cancer 20100101

A phase I study of the nitroimidazole hypoxia marker SR4554 using 19F magnetic resonance spectroscopy.

British journal of cancer 20091201

Contribution of HIF-1 and drug penetrance to oxaliplatin resistance in hypoxic colorectal cancer cells.

British journal of cancer 20091020

Spin trapping of radicals other than the *OH radical upon reduction of the anticancer agent tirapazamine by cytochrome P450 reductase.

Journal of the American Chemical Society 20091014

Molecular imaging of hypoxia with radiolabelled agents.

European journal of nuclear medicine and molecular imaging 20091001

Increased tumor oxygenation and drug uptake during anti-angiogenic weekly low dose cyclophosphamide enhances the anti-tumor effect of weekly tirapazamine.

Current cancer drug targets 20090901

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20090901

Ultrasensitive electrochemical sensing of the anticancer drug tirapazamine using an ordered mesoporous carbon modified pyrolytic graphite electrode.

Biosensors & bioelectronics 20090715

Detecting vascular-targeting effects of the hypoxic cytotoxin tirapazamine in tumor xenografts using magnetic resonance imaging.

International journal of radiation oncology, biology, physics 20090701

Phase II study of tirapazamine, cisplatin, and etoposide and concurrent thoracic radiotherapy for limited-stage small-cell lung cancer: SWOG 0222.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090620

Evaluation of the potential of hexamethylenetetramine, compared with tirapazamine, as a combined agent with {gamma}-irradiation and cisplatin treatment in vivo.

The British journal of radiology 20090501

Effects of cytokine-induced macrophages on the response of tumor cells to banoxantrone (AQ4N).

Molecular cancer therapeutics 20090501

Structural adaptation and heterogeneity of normal and tumor microvascular networks.

PLoS computational biology 20090501

Cytotoxic palladium complexes of bioreductive quinoxaline N1,N4-dioxide prodrugs.

Bioorganic & medicinal chemistry 20090215

Initiation of DNA strand cleavage by 1,2,4-benzotriazine 1,4-dioxide antitumor agents: mechanistic insight from studies of 3-methyl-1,2,4-benzotriazine 1,4-dioxide.

Journal of the American Chemical Society 20090128

A phase I pharmacokinetic study of hypoxic abdominal stop-flow perfusion with gemcitabine in patients with advanced pancreatic cancer and refractory malignant ascites.

Cancer chemotherapy and pharmacology 20090101

Tirapazamine: a novel agent targeting hypoxic tumor cells.

Expert opinion on investigational drugs 20090101

Synthesis, cytotoxic activity, and DNA binding properties of copper (II) complexes with hesperetin, naringenin, and apigenin.

Bioinorganic chemistry and applications 20090101

A Model for NAD(P)H:Quinoneoxidoreductase 1 (NQO1) Targeted Individualized Cancer Chemotherapy.

Drug target insights 20090101

A dialogue between the hypoxia-inducible factor and the tumor microenvironment.

Cancer microenvironment : official journal of the International Cancer Microenvironment Society 20081201

Tricyclic [1,2,4]triazine 1,4-dioxides as hypoxia selective cytotoxins.

Journal of medicinal chemistry 20081113

Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20081010

Quantitative measure of cytotoxicity of anticancer drugs and other agents.

Analytical biochemistry 20081001

Synthesis and biological activity of 1-methyl-tryptophan-tirapazamine hybrids as hypoxia-targeting indoleamine 2,3-dioxygenase inhibitors.

Bioorganic & medicinal chemistry 20080915

iNOS as a therapeutic target for treatment of human tumors.

Nitric oxide : biology and chemistry 20080901

Hypoxia-specific drug tirapazamine does not abrogate hypoxic tumor cells in combination therapy with irinotecan and methylselenocysteine in well-differentiated human head and neck squamous cell carcinoma a253 xenografts.

Neoplasia (New York, N.Y.) 20080801

In vivo 1H magnetic resonance spectroscopy of lactate in patients with stage IV head and neck squamous cell carcinoma.

International journal of radiation oncology, biology, physics 20080715

[Can tumor hypoxia be turned into a chemotherapeutic advantage?].

Bulletin du cancer 20080501

Carbonic anhydrase 9 (CA9) expression in tumor cells enhances sensitivity to tirapazamine.

Journal of cancer research and clinical oncology 20080301

Exploring vascular dysfunction caused by tirapazamine.

Microvascular research 20080301

Evaluation of the antiangiogenic potential of AQ4N.

Clinical cancer research : an official journal of the American Association for Cancer Research 20080301

Hypoxic tumor cell radiosensitization: role of the iNOS/NO pathway.

Bulletin du cancer 20080301

Tirapazamine plus cisplatin and irradiation in a mouse model: improved tumor control at the cost of increased toxicity.

Journal of cancer research and clinical oncology 20080201

A review of topotecan in combination chemotherapy for advanced cervical cancer.

Therapeutics and clinical risk management 20080201

Homologous recombination is the principal pathway for the repair of DNA damage induced by tirapazamine in mammalian cells.

Cancer research 20080101

[The Oxygen effect: an old new target?].

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique 20080101

Detection and specific targeting of hypoxic regions within solid tumors: current preclinical and clinical strategies.

Current medicinal chemistry 20080101

Pharmacokinetic/pharmacodynamic model-guided identification of hypoxia-selective 1,2,4-benzotriazine 1,4-dioxides with antitumor activity: the role of extravascular transport.

Journal of medicinal chemistry 20071213

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20071201

DNA strand damage product analysis provides evidence that the tumor cell-specific cytotoxin tirapazamine produces hydroxyl radical and acts as a surrogate for O(2).

Journal of the American Chemical Society 20071024

Oxygen dependence and extravascular transport of hypoxia-activated prodrugs: comparison of the dinitrobenzamide mustard PR-104A and tirapazamine.

International journal of radiation oncology, biology, physics 20071001

Chemical radiosensitizers for use in radiotherapy.

Clinical oncology (Royal College of Radiologists (Great Britain)) 20070801

Bioreductive drugs: from concept to clinic.

Clinical oncology (Royal College of Radiologists (Great Britain)) 20070801

Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104.

Clinical cancer research : an official journal of the American Association for Cancer Research 20070701

Adenovirus-mediated hypoxia-targeting cytosine deaminase gene therapy enhances radiotherapy in tumour xenografts.

British journal of cancer 20070618

Bystander effects of bioreductive drugs: potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustards.

Radiation research 20070601

Beyond detection: novel applications for PET imaging to guide cancer therapy.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20070601

Pretreatment 18F-FAZA PET predicts success of hypoxia-directed radiochemotherapy using tirapazamine.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20070601

Increased nanoparticle penetration in collagenase-treated multicellular spheroids.

International journal of nanomedicine 20070601

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20070601

[Inhibitory effect of tirapazamine combined with phosphatidylinositol 3-kinase inhibitor LY294002 to ovarian cancer cells].

Zhonghua yi xue za zhi 20070508

Synthesis, structure and hypoxic cytotoxicity of 3-amino-1,2,4-benzotriazine-1,4-dioxide derivatives.

Archiv der Pharmazie 20070501

On the mechanism of reaction of radicals with tirapazamine.

Journal of the American Chemical Society 20070418

Phase I trial of tirapazamine, cisplatin, and concurrent accelerated boost reirradiation in patients with recurrent head and neck cancer.

International journal of radiation oncology, biology, physics 20070301

Effects of fluctuating oxygenation on tirapazamine efficacy: Theoretical predictions.

International journal of radiation oncology, biology, physics 20070201

The concurrent chemoradiation paradigm--general principles.

Nature clinical practice. Oncology 20070201

Assessment of DNA damage at the dimer level: measurement of the formamide lesion.

Radiation research 20070201

The usefulness of mild temperature hyperthermia combined with continuous tirapazamine administration under reduced dose-rate irradiation with gamma-rays.

International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 20070201

Dependency of the effect of a vascular disrupting agent on sensitivity to tirapazamine and gamma-ray irradiation upon the timing of its administration and tumor size, with reference to the effect on intratumor quiescent cells.

Journal of cancer research and clinical oncology 20070101

Radiosensitization by 2-benzoyl-3-phenyl-6,7-dichloroquinoxaline 1,4-dioxide under oxia and hypoxia in human colon cancer cells.

Radiation oncology (London, England) 20070101

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20070101

DNA repair mechanisms are involved in the hypoxia-dependent toxicity of NLCQ-1 (NSC 709257) and its synergistic interaction with alkylating agents.

In vivo (Athens, Greece) 20070101

Identifying and targeting hypoxia in head and neck cancer: a brief overview of current approaches.

International journal of radiation oncology, biology, physics 20070101

Hypoxia in head and neck cancer: studies with hypoxic positron emission tomography imaging and hypoxic cytotoxins.

International journal of radiation oncology, biology, physics 20070101

Tumor hypoxia in cancer therapy.

Methods in enzymology 20070101

Breast tumour angiogenesis.

Breast cancer research : BCR 20070101

Bevacizumab: the evidence for its clinical potential in the treatment of nonsmall cell lung cancer.

Core evidence 20070101

The usefulness of a continuous administration of tirapazamine combined with reduced dose-rate irradiation using {gamma}-rays or reactor thermal neutrons.

The British journal of radiology 20061201

New quinoxaline 1,4-di-N-oxides. Part 1: Hypoxia-selective cytotoxins and anticancer agents derived from quinoxaline 1,4-di-N-oxides.

Bioorganic & medicinal chemistry 20061015

Complete 1H, 13C and 15N NMR assignment of tirapazamine and related 1,2,4-benzotriazine N-oxides.

Magnetic resonance in chemistry : MRC 20061001

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20061001

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20060901

Respecting cancer drug transportability: a basis for successful lead selection.

Journal of the National Cancer Institute 20060816

Use of three-dimensional tissue cultures to model extravascular transport and predict in vivo activity of hypoxia-targeted anticancer drugs.

Journal of the National Cancer Institute 20060816

Selective hypoxia-cytotoxins based on vanadyl complexes with 3-aminoquinoxaline-2-carbonitrile-N1,N4-dioxide derivatives.

Journal of inorganic biochemistry 20060801

Hypoxia: targeting the tumour.

Anti-cancer agents in medicinal chemistry 20060701

Concurrent chemoradiotherapy for locally advanced, nonmetastatic, squamous carcinoma of the head and neck: consensus, controversy, and conundrum.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060610

Mature results from a randomized Phase II trial of cisplatin plus 5-fluorouracil and radiotherapy with or without tirapazamine in patients with resectable Stage IV head and neck squamous cell carcinomas.

Cancer 20060501

Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060501

[Evaluation of the toxicity of tirapazamine plus cisplatin in a mouse tumor model].

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] 20060401

A phase II evaluation of tirapazamine plus cisplatin in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.

Gynecologic oncology 20060301

Radiation sensitization with redox modulators: a promising approach.

International journal of radiation oncology, biology, physics 20060201

Low-dose metronomic daily cyclophosphamide and weekly tirapazamine: a well-tolerated combination regimen with enhanced efficacy that exploits tumor hypoxia.

Cancer research 20060201

Tirapazamine causes vascular dysfunction in HCT-116 tumour xenografts.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 20060201

[Study on HPLC determination method and pharmacokinetics of tirapazaming in rabbits].

Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi 20060201

Potentiation of the cytotoxicity of the anticancer agent tirapazamine by benzotriazine N-oxides: the role of redox equilibria.

Journal of the American Chemical Society 20060111

Tirapazamine plus cisplatin in advanced or recurrent carcinoma of the uterine cervix: a Southwest Oncology Group study.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20060101

Global analysis of gene function in yeast by quantitative phenotypic profiling.

Molecular systems biology 20060101

Phase II study of tirapazamine plus cisplatin in patients with advanced or recurrent cervical cancer.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20060101

Potentiation of alkylating agents by NLCQ-1 or TPZ in vitro and in vivo.

Journal of experimental therapeutics & oncology 20060101

Tirapazamine: from bench to clinical trials.

Current clinical pharmacology 20060101

Update on clinical radiobiology.

Biomedical imaging and intervention journal 20060101

Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20051220

Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent.

European journal of nuclear medicine and molecular imaging 20051201

Synthesis of 3-amino-1,2,4-benzothiadi- azine 1,1-dioxides via a tandem aza-Wittig/heterocumulene annulation.

The Journal of organic chemistry 20051125

Large-scale analysis of genes that alter sensitivity to the anticancer drug tirapazamine in Saccharomyces cerevisiae.

Molecular pharmacology 20051101

Resistance to endocrine therapy in breast cancer.

Cancer chemotherapy and pharmacology 20051101

[Determination of the related substances in tirapazamine by high performance liquid chromatography].

Se pu = Chinese journal of chromatography 20051101

Anemia, tumor hypoxemia, and the cancer patient.

International journal of radiation oncology, biology, physics 20050901

Combination of the antivascular agent ZD6126 with hypoxic cytotoxin treatment, with reference to the effect on quiescent tumor cells and the dependency on p53 status of tumor cells.

Oncology reports 20050801

The role of bioreductive activation of doxorubicin in cytotoxic activity against leukaemia HL60-sensitive cell line and its multidrug-resistant sublines.

British journal of cancer 20050711

Hypoxia in head and neck cancer: how much, how important?

Head & neck 20050701

Observation of incipient tumor angiogenesis that is independent of hypoxia and hypoxia inducible factor-1 activation.

Cancer research 20050701

Radical properties governing the hypoxia-selective cytotoxicity of antitumor 3-amino-1,2,4-benzotriazine 1,4-dioxides.

Organic & biomolecular chemistry 20050607

Tirapazamine administered as a neoadjuvant to radiotherapy reduces metastatic dissemination.

Clinical cancer research : an official journal of the American Association for Cancer Research 20050601

The usefulness of continuous administration of hypoxic cytotoxin combined with mild temperature hyperthermia, with reference to effects on quiescent tumour cell populations.

International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 20050601

Tirapazamine cytotoxicity for neuroblastoma is p53 dependent.

Clinical cancer research : an official journal of the American Association for Cancer Research 20050401

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20050401

Time-resolved spectroscopy of the excited singlet states of tirapazamine and desoxytirapazamine.

The journal of physical chemistry. A 20050303

Tirapazamine with cisplatin and vinorelbine in patients with advanced non-small-cell lung cancer: a phase I/II study.

Clinical lung cancer 20050301

Extravascular transport of drugs in tumor tissue: effect of lipophilicity on diffusion of tirapazamine analogues in multicellular layer cultures.

Journal of medicinal chemistry 20050224

Tirapazamine, Cisplatin, and Radiation versus Fluorouracil, Cisplatin, and Radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02).

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050101

Improving survival and reducing toxicity with chemotherapy in advanced non-small cell lung cancer : a realistic goal?

Treatments in respiratory medicine 20050101

Radiosensitising effect of electrochemotherapy with bleomycin in LPB sarcoma cells and tumors in mice.

BMC cancer 20050101

Prodrug research: futile or fertile?

Biochemical pharmacology 20041201

The Japanese experiences with hypoxia-targeting pharmacoradiotherapy: from hypoxic cell sensitisers to radiation-activated prodrugs.

Expert opinion on pharmacotherapy 20041201

[Phase II-trial of tirapazamine in combination with cisplatin and gemcitabine in patients with advanced non-small-cell-lung-cancer (NSCLC)].

Pneumologie (Stuttgart, Germany) 20041201

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20041201

Enzyme-activated, hypoxia-selective DNA damage by 3-amino-2-quinoxalinecarbonitrile 1,4-di-N-oxide.

Chemical research in toxicology 20041101

Combined chemotherapy and radiation therapy for cervical cancer.

Journal of the National Comprehensive Cancer Network : JNCCN 20041101

Dietary induction of NQO1 increases the antitumour activity of mitomycin C in human colon tumours in vivo.

British journal of cancer 20041018

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20041001

Microenvironmental adaptation of experimental tumours to chronic vs acute hypoxia.

British journal of cancer 20040913

Prospects for hypoxia-activated anticancer drugs.

Current medicinal chemistry. Anti-cancer agents 20040901

Cytochrome P450 CYP1B1 activity in renal cell carcinoma.

British journal of cancer 20040831

Phase I study of tirapazamine plus cisplatin/etoposide and concurrent thoracic radiotherapy in limited-stage small cell lung cancer (S0004): a Southwest Oncology Group study.

Clinical cancer research : an official journal of the American Association for Cancer Research 20040815

Phosphorylated histone H2AX in spheroids, tumors, and tissues of mice exposed to etoposide and 3-amino-1,2,4-benzotriazine-1,3-dioxide.

Cancer research 20040801

Enhanced effectiveness of radiochemotherapy with tirapazamine by local application of electric pulses to tumors.

Radiation research 20040801

Clinical studies of hypoxia modification in radiotherapy.

Seminars in radiation oncology 20040701

Oxidation of 2-deoxyribose by benzotriazinyl radicals of antitumor 3-amino-1,2,4-benzotriazine 1,4-dioxides.

Journal of the American Chemical Society 20040630

Oxygen dependence of the metabolic activation and cytotoxicity of tirapazamine: implications for extravascular transport and activity in tumors.

Radiation research 20040601

New derivatives of quinazoline and 1, 2-dihydroquinazoline n3-oxide with expected antitumor activity.

Archiv der Pharmazie 20040501

1, 2, 4-Triazine N-oxide derivatives: studies as potential hypoxic cytotoxins. Part II.

Archiv der Pharmazie 20040501

1, 2, 4-Triazine N-oxide derivatives: studies as potential hypoxic cytotoxins. Part III.

Archiv der Pharmazie 20040501

Phase I trial of tirapazamine and cyclophosphamide in children with refractory solid tumors: a pediatric oncology group study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20040415

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20040401

2-Amino metabolites are key mediators of CB 1954 and SN 23862 bystander effects in nitroreductase GDEPT.

British journal of cancer 20040308

Enzyme-catalyzed activation of anticancer prodrugs.

Pharmacological reviews 20040301

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20040301

Hypoxia targeted gene therapy to increase the efficacy of tirapazamine as an adjuvant to radiotherapy: reversing tumor radioresistance and effecting cure.

Cancer research 20040215

DNA-targeted 1,2,4-benzotriazine 1,4-dioxides: potent analogues of the hypoxia-selective cytotoxin tirapazamine.

Journal of medicinal chemistry 20040115

Selective potentiation of the hypoxic cytotoxicity of tirapazamine by its 1-N-oxide metabolite SR 4317.

Cancer research 20040115

The importance of DT-diaphorase and hypoxia in the cytotoxicity of RH1 in human breast and non-small cell lung cancer cell lines.

Anti-cancer drugs 20040101

Efficacy of cytotoxic agents used in the treatment of testicular germ cell tumours under normoxic and hypoxic conditions in vitro.

British journal of cancer 20031201

Endogenous markers of tumor hypoxia predictors of clinical radiation resistance?

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] 20031201

NLCQ-1 (NSC 709257): exploiting hypoxia with a weak DNA-intercalating bioreductive drug.

Clinical cancer research : an official journal of the American Association for Cancer Research 20031115

Enhanced conversion of DNA radical damage to double strand breaks by 1,2,4-benzotriazine 1,4-dioxides linked to a DNA binder compared to tirapazamine.

Chemical research in toxicology 20031101

The expression of P-glycoprotein does influence the distribution of novel fluorescent compounds in solid tumour models.

British journal of cancer 20031020

Human NADPH-cytochrome p450 reductase overexpression does not enhance the aerobic cytotoxicity of doxorubicin in human breast cancer cell lines.

Cancer research 20031015

Tirapazamine plus carboplatin and paclitaxel in advanced malignant solid tumors: a california cancer consortium phase I and molecular correlative study.

Clinical cancer research : an official journal of the American Association for Cancer Research 20031001

DNA base damage by the antitumor agent 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine).

Journal of the American Chemical Society 20030924

Multicellular resistance to tirapazamine is due to restricted extravascular transport: a pharmacokinetic/pharmacodynamic study in HT29 multicellular layer cultures.

Cancer research 20030915

Professor Tom Connors and the development of novel cancer therapies by the Phase I/II Clinical Trials Committee of Cancer Research UK.

British journal of cancer 20030804

A mass spectrometry study of tirapazamine and its metabolites. insights into the mechanism of metabolic transformations and the characterization of reaction intermediates.

Journal of the American Society for Mass Spectrometry 20030801

A simple method of producing low oxygen conditions with oxyrase for cultured cells exposed to radiation and tirapazamine.

American journal of clinical oncology 20030801

Expression of phosphorylated histone H2AX as a surrogate of cell killing by drugs that create DNA double-strand breaks.

Cancer research 20030801

Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies.

Cancer treatment reviews 20030801

Comparison of the comet assay and the oxygen microelectrode for measuring tumor oxygenation in head-and-neck cancer patients.

International journal of radiation oncology, biology, physics 20030601

Non-nuclear localized human NOSII enhances the bioactivation and toxicity of tirapazamine (SR4233) in vitro.

Molecular pharmacology 20030601

Improved potency of the hypoxic cytotoxin tirapazamine by DNA-targeting.

Biochemical pharmacology 20030601

Antagonism of buthionine sulfoximine cytotoxicity for human neuroblastoma cell lines by hypoxia is reversed by the bioreductive agent tirapazamine.

Cancer research 20030401

Photochemical and photobiological studies of tirapazamine (SR 4233) and related quinoxaline 1,4-Di-N-oxide analogues.

Chemical research in toxicology 20030201

Activation of 3-amino-1,2,4-benzotriazine 1,4-dioxide antitumor agents to oxidizing species following their one-electron reduction.

Journal of the American Chemical Society 20030122

Structure-activity relationships of 1,2,4-benzotriazine 1,4-dioxides as hypoxia-selective analogues of tirapazamine.

Journal of medicinal chemistry 20030102

Potential of alpha-amino alcohol p-boronophenylalaninol as a boron carrier in boron neutron capture therapy, regarding its enantiomers.

Journal of cancer research and clinical oncology 20030101

Usefulness of combined treatment with mild temperature hyperthermia and/or tirapazamine in the treatment of solid tumors: its independence of p53 status.

Cancer science 20030101

Antiangiogenic hypoxic cytotoxin TX-402 inhibits hypoxia-inducible factor 1 signaling pathway.

Anticancer research 20030101

Therapeutic advantage from combining paclitaxel with the hypoxia-selective cytotoxin NLCQ-1 in murine tumor- or human xenograft-bearing mice.

Cancer chemotherapy and pharmacology 20021201

Platinum drugs in the treatment of non-small-cell lung cancer.

British journal of cancer 20021007

Therapeutic advantage from combining 5-fluorouracil with the hypoxia-selective cytotoxin NLCQ-1 in vivo; comparison with tirapazamine.

Cancer chemotherapy and pharmacology 20021001

Tirapazamine: a hypoxia-activated topoisomerase II poison.

Cancer research 20020915

Oxidative DNA base damage by the antitumor agent 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine).

Bioorganic & medicinal chemistry letters 20020902

5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy.

Investigational new drugs 20020801

Carbogen breathing after irradiation enhances the effectiveness of tirapazamine in SiHa tumors but not SCCVII tumors in mice.

Radiation research 20020701

Design, synthesis and biological activities of antiangiogenic hypoxic cytotoxin, triazine-N-oxide derivatives.

Comparative biochemistry and physiology. Part A, Molecular & integrative physiology 20020501

Photochemical electron transfer reactions of tirapazamine.

Photochemistry and photobiology 20020401

Significance of the response of quiescent cell populations within solid tumors in cancer therapy.

Journal of radiation research 20020301

The effect of functional groups on reduction and activation of quinone bioreductive agents by DT-diaphorase.

Cancer chemotherapy and pharmacology 20020201

Local hypoxia is produced at sites of intratumour injection.

British journal of cancer 20020201

Tirapazamine: prototype for a novel class of therapeutic agents targeting tumor hypoxia.

Seminars in oncology 20020201

Synergistic enhancement of the antitumor effect of taxol by the bioreductive compound NLCQ-1, in vivo: comparison with tirapazamine.

Oncology research 20020101

Hypoxic active drugs.

I supplementi di Tumori : official journal of Societa italiana di cancerologia ... [et al.] 20020101

Tumor microenvironment and the response to anticancer therapy.

Cancer biology & therapy 20020101

Metabolism of tirapazamine by multiple reductases in the nucleus.

Biochemical pharmacology 20011101

Optimizing the use of combined radioimmunotherapy and hypoxic cytotoxin therapy as a function of tumor hypoxia.

International journal of cancer 20011101

Evaluation of the potential of p-boronophenylalaninol as a boron carrier in boron neutron capture therapy, referring to the effect on intratumor quiescent cells.

Japanese journal of cancer research : Gann 20010901

Indications for chemotherapy in stage IV non-small cell lung cancer.

Lung cancer (Amsterdam, Netherlands) 20010901

Modeling the action of an antitumor drug: a density functional theory study of the mechanism of tirapazamine.

Journal of the American Chemical Society 20010801

Effects of anticancer drugs on the metabolism of the anticancer drug 5,6-dimethylxanthenone-4-acetic (DMXAA) by human liver microsomes.

British journal of clinical pharmacology 20010801

The chemopotentiation of cisplatin by the novel bioreductive drug AQ4N.

British journal of cancer 20010801

Schedule-dependent potentiation of chemotherapeutic drugs by the bioreductive compounds NLCQ-1 and tirapazamine against EMT6 tumors in mice.

Cancer chemotherapy and pharmacology 20010801

Selective interaction of tirapazamine with DNA bases and DNA. A comparison of cyclic voltammetry and electrolysis techniques.

Free radical research 20010801

Radiosensitization effect by combination with paclitaxel in vivo, including the effect on intratumor quiescent cells.

International journal of radiation oncology, biology, physics 20010715

Inhibition of DNA replication by tirapazamine.

Cancer research 20010715

Phase I trial of i.v. administered tirapazamine plus cyclophosphamide.

Anti-cancer drugs 20010701

Recent advances in the chemotherapy of non-small cell lung cancer.

Japanese journal of clinical oncology 20010701

Electron transfer and oxidative stress as key factors in the design of drugs selectively active in hypoxia.

Current medicinal chemistry 20010601

Triplet combination chemotherapy and targeted therapy regimens.

Oncology (Williston Park, N.Y.) 20010301

Therapeutic targets in radiotherapy.

International journal of radiation oncology, biology, physics 20010201

Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010115

3-amino-1,2,4-benzotriazine 4-oxide: characterization of a new metabolite arising from bioreductive processing of the antitumor agent 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine).

The Journal of organic chemistry 20010112

Analysis of DNA damage in individual cells.

Methods in cell biology 20010101

An investigation of the molecular basis for the synergistic interaction of tirapazamine and cisplatin.

International journal of radiation oncology, biology, physics 20010101

Mitochondrial dysfunction after aerobic exposure to the hypoxic cytotoxin tirapazamine.

Cancer research 20010101

Cytotoxicity of bioreductive drug tirapazamine is increased by application of electric pulses in SA-1 tumours in mice.

Anticancer research 20010101

4-[3-(2-Nitro-1-imidazolyl)propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive agent as radiosensitizer in vitro and in vivo: comparison with tirapazamine.

Oncology research 20010101

Hypoxia and oxidative stress. Tumour hypoxia--therapeutic considerations.

Breast cancer research : BCR 20010101

Targeting hypoxia in head and neck cancer.

Acta oncologica (Stockholm, Sweden) 20010101

Combination of the bioreductive drug tirapazamine with the chemotherapeutic prodrug cyclophosphamide for P450/P450-reductase-based cancer gene therapy.

Cancer research 20000715

Molecular mechanisms of tirapazamine (SR 4233, Win 59075)-induced hepatocyte toxicity under low oxygen concentrations.

British journal of cancer 19950401

SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells.

International journal of radiation oncology, biology, physics 19860701